SBFM Stock Analysis: Buy, Sell, or Hold?
SBFM - Sunshine Biopharma Inc.
$0.51
0.23 (79.51%)
▲
5d:
-50.49%
30d:
-50.49%
90d:
-56.03%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 21, 2026
1d
Get Alerted When SBFM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
18 traders called SBFM this week
70% bullish • 6 bearish
70% bullish • 6 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SBFM trades at premium valuation expecting 21.5% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: SBFM trades at premium valuation expecting 21.5% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: SBFM is currently trading at $0.51, which is considered oversold relative to its 30-day fair value range of $0.74 to $1.14. From a valuation perspective, the stock is trading at a premium (Forward PE: 25.5) compared to its historical average (14.2). At these levels, the market is pricing in 21.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SBFM is in a downtrend. Immediate support is located at $0.28, while resistance sits at $2.32. The stock is showing strong short-term momentum, up 79.5% recently.
Market Sentiment: SBFM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.60 (+998.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SBFM is in a downtrend. Immediate support is located at $0.28, while resistance sits at $2.32. The stock is showing strong short-term momentum, up 79.5% recently.
Market Sentiment: SBFM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.60 (+998.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.74 -
$1.14
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
56.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: Strong upward momentum (+79.5%)
- BULLISH: Trading 998.0% below Wall St target ($5.60)
- NEUTRAL: Trading at premium valuation - market expects 21.5% growth which is achievable
- CAUTION: 5-day price weakness (-50.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.74 -
$1.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.28
Resistance Level
$2.32
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.50
Wall Street Target
$5.60
(+998.0%)
Revenue Growth (YoY)
-9.1%
Profit Margin
-17.0%
Valuation Premium vs History
+21.5% premium
PE vs Historical
25.5 vs 14.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.5%
(market-implied from PE analysis)
1-Year Target
$0.62
(+22%)
2-Year Target
$0.75
(+48%)
3-Year Target
$0.91
(+79%)
3-Yr Target (if PE normalizes)
(PE: 26→14)
PE COMPRESSION
$0.51
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: May 19, 2026 12:53 AM ET
Data refreshes hourly during market hours. Next update: 1:53 AM
Data refreshes hourly during market hours. Next update: 1:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SBFM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 55 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 54 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$40 | 58 HOLD |
